Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussions reflect strong enthusiasm and engagement, with many examples citing the trial's promising results—such as improved exercise capacity and symptom relief—and emphasizing the potential for aficamten to be a transformative therapy. The tone is optimistic and professional, underlining its clinical significance and the excitement surrounding new advances in hypertrophic cardiomyopathy treatment.
Most discussions express positive support and recognition of the trial results, with many emphasizing the significance of aficamten's improvements.
Posts display high interest, highlighting details of the clinical trial and potential clinical implications, with phrases like 'game changer' and 'best trial 2024'.
The discourse shows deep engagement through sharing specific outcomes, references to guidelines, and professional interactions, indicating active involvement.
Participants believe the study could significantly influence treatment options and patient outcomes, as reflected in comments about breakthroughs and future guidelines.
Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d Editorial: Sixty Years of Hemodynamic Pharmacology in Obstructive Hypertrophic Cardiomyopathy https://t.co/xrmOdxMrpX #HeartFailure2024 @escardio https://t.co/pV8aOpMCpc
In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Read the full trial results and Plain Language Summary: https://t.co/8M0wEtJ96d https://t.co/eTukeCufQ6
Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d Editorial: Sixty Years of Hemodynamic Pharmacology in Obstructive Hypertrophic Cardiomyopathy https://t.co/xrmOdxMrpX #Cardiology https://t.co/sVdhc9L4Mp
Best of Heart Failure 2024 Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Among patients with symptomatic obstructive HCM, treatment with aficamten resulted in a significantly greater improvement in peak oxygen uptake than placebo https://t.co/uaU5N2sSgc https://t.co/7d1FRKkGkC
This video explains the science behind aficamten, a cardiac myosin inhibitor approved for symptomatic obstructive hypertrophic cardiomyopathy, discussing how it reduces heart muscle contraction and improves exercise…
How Aficamten (MYQORZO ®) Works in Obstructive Hypertrophic Cardiomyopathy https://t.co/Worr6NRSID #MedicalEducation #Pharmacology #Cardiology #CardiacMyosinInhibitor
From bench to beside
RT @MasriAhmadMD: Here are the primary results of #aficamten in @NEJM https://t.co/l25f6RiUaS #HeartFailure2024 #CardioTwitter https://t…
RT @CardiopatiasH: Congratulations to the Cytokinetics team! #Aficamten impressive results published in the top Medical Journal. New Era fo…
RT @drbennisahmed: Best Trial 2024 Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Among patients with symptomatic obst…
Best Trial 2024 Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Among patients with symptomatic obstructive HCM, treatment with aficamten resulted in a significantly greater improvement in peak oxygen uptake than placebo https://t.co/uaU5N2sSgc https://t.co/TIBy7Vd6WT
Best of Heart Failure 2024 Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Among patients with symptomatic obstructive HCM, treatment with aficamten resulted in a significantly greater improvement in peak oxygen uptake than placebo https://t.co/uaU5N2sSgc https://t.co/7d1FRKkGkC
Link to Full Article: https://t.co/YumSXm9pEe #CardsJC
En un primer momento, nos pareció un ensayo al que poner pocas pegas, con aceptables validez interna y externa. El problema principal lo encontramos al intentar valorar el efecto y su relevancia clínica... ¿Qué es el pkVO2? ¿es 1.7 ml/kg/min relevante?https://t.co/7ak2g5EMrX
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy https://t.co/Qnq2G8AZOX
O Grupo de Estudo de Doenças do Miocárdio e Pericárdio destaca, como artigo do mês, o estudo “Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy”.
2 min cardiology（臨床論文、担当：薄田海） Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy M S Maron et al. NEJM 2024; 390: 1849-61 https://t.co/J9XHqbHfzh →
New study shows aficamten significantly improves exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). https://t.co/88umejpzGp
RT @twmu_cardiology:
RT @AugoustidesJohn: #HOCMVista Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https:…
RT @twmu_cardiology:
RT @MondaEmanuele: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy @NEJM https://t.co/vBd9uSv1JH https://t.co/VQGqb7mJ…
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy @NEJM https://t.co/vBd9uSv1JH https://t.co/VQGqb7mJxc
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy https://t.co/SNUJs3zo1i #PublicaSergas #CHUAC
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy https://t.co/s1H4jwJw6l. Great News !! @smexcardiologia HCM Guidelines in Mexico next @SIAC_cardio congress june 5-7 2024 @adribaran
#HOCMVista Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/wj8X5sA7c1
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
RT @NEJM: In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructi…
In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Read the full trial results and Plain Language Summary: https://t.co/8M0wEtJ96d https://t.co/eTukeCufQ6
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/rW1FTenMZA
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
#clinicalquestion Class effect or is there a specific difference between Mavacamten and Aficamten? https://t.co/3nWjpc0rJl @NEJM @CardioNerds @MKIttlesonMD
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
Potentially fantastic breakthrough for pts with #H_O_CM with #LVOT>30mmHg at rest and >50mmHg after Valsava manoeuvre in #Aficamten improving #Peak_VO2/#NYHA class/#KCCQ at 24/52 @NEJM #MartinSMoran #AhmadMasri #CardiTwitter https://t.co/dtYH0ZtGRQ
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/RHeTIJsHJX
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy $CYTK |NEJM https://t.co/RfKhrcFJRD https://t.co/4Q8XQYfSfk
Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d Editorial: Sixty Years of Hemodynamic Pharmacology in Obstructive Hypertrophic Cardiomyopathy https://t.co/xrmOdxMrpX #Cardiology https://t.co/sVdhc9L4Mp
RT @NEJM: @MartinMaronMD Read the research findings by @MartinMaronMD et al. in the Original Article “Aficamten for Symptomatic Obstructive…
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/uM3YirauKN
@MartinMaronMD Read the research findings by @MartinMaronMD et al. in the Original Article “Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy”: https://t.co/8M0wEtJ96d #Cardiology
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | comment: Martin S. Maron MD https://t.co/AJwqyiqsCP via @practiceupdate
RT @2minmed: #VisualAbstract: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy https://t.co/ZjhtwD9Pqk #StudyGraphics #afi…
#VisualAbstract: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy https://t.co/ZjhtwD9Pqk #StudyGraphics #aficamten https://t.co/OycCx933hu
Trending on PubMed: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. https://t.co/lGLBrKkLu8
RT @MasriAhmadMD: Here are the primary results of #aficamten in @NEJM https://t.co/l25f6RiUaS #HeartFailure2024 #CardioTwitter https://t…
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy #science #publication #research #journal https://t.co/K2yc4HA9G1
RT @CardiopatiasH: Congratulations to the Cytokinetics team! #Aficamten impressive results published in the top Medical Journal. New Era fo…
RT @KhalidFAlhabib: https://t.co/cxsEofWHFa
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Among patients with symptomatic obstructive HCM, treatment with aficamten resulted in a significantly greater improvement in peak oxygen uptake than placebo Best of 2024 https://t.co/uaU5N2skqE
RT @CardiopatiasH: Congratulations to the Cytokinetics team! #Aficamten impressive results published in the top Medical Journal. New Era fo…
RT @CardiopatiasH: Congratulations to the Cytokinetics team! #Aficamten impressive results published in the top Medical Journal. New Era fo…
RT @MasriAhmadMD: Here are the primary results of #aficamten in @NEJM https://t.co/l25f6RiUaS #HeartFailure2024 #CardioTwitter https://t…
RT @CardiopatiasH: Congratulations to the Cytokinetics team! #Aficamten impressive results published in the top Medical Journal. New Era fo…
Congratulations to the Cytokinetics team! #Aficamten impressive results published in the top Medical Journal. New Era for patients with Hypertrophic CM, thanks to Mavacamten & Aficamten https://t.co/8l2s8QSD34 https://t.co/rxuUbUoKdE
https://t.co/cxsEofWHFa
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/eU9VI0TOMr
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Presented at #HeartFailure2024: Among patients with symptomatic obstructive hypertrophic cardiomyopathy, treatment with aficamt…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @MasriAhmadMD: Here are the primary results of #aficamten in @NEJM https://t.co/l25f6RiUaS #HeartFailure2024 #CardioTwitter https://t…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @CMichaelGibson: Among patients with symptomatic obstructive HCM, treatment with #aficamten resulted in a significantly greater improve…
RT @NEJM: Presented at #HeartFailure2024: Among patients with symptomatic obstructive hypertrophic cardiomyopathy, treatment with aficamt…
RT @FranBermudz: #Aficamten for Symptomatic #OHCM in @NEJM
RT @MeliAntoniolli: Una nueva alternativa p/pac. con MCH obstructiva ❗️282
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Presented at #HeartFailure2024: Among patients with symptomatic obstructive hypertrophic cardiomyopathy, treatment with aficamt…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Presented at #HeartFailure2024: Among patients with symptomatic obstructive hypertrophic cardiomyopathy, treatment with aficamt…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
RT @NEJM: Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d…
Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) https://t.co/8M0wEtJ96d Editorial: Sixty Years of Hemodynamic Pharmacology in Obstructive Hypertrophic Cardiomyopathy https://t.co/xrmOdxMrpX #HeartFailure2024 @escardio https://t.co/pV8aOpMCpc
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/rC58krRf1z
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | NEJM LVOT gradient remains the same. ??? https://t.co/PTsaVBq3AU https://t.co/NtGjUPdiCG
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/PTsaVBq3AU https://t.co/XZgv1BWC5s
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/2EFb4Fr9TJ
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/IzuMAwPidx Amazing work! I feel lucky that I got to interact with Dr. Abraham in med school during research electives at Hopkins & UCSF -- so much to learn from him!
8. Journal The New England Journal of Medicine **utilizing generative AI: ChatGPT-4o** https://t.co/yxrYi6ng1J
RT @ZHeart11768530:
#Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/HpT34bicol
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine https://t.co/NRkRHfe6Io
Dose Update: Attention! Cytokinetics ($CYTK
Cytokinetics Announces Crucial Development in Pediatric Cardiology Treatment: Clinical Trial of Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Now Open for Enrollment:… https://t.co/i49tLMnUvD #biotechnology #MajorPharmaceuticalPreparations #suppliers #News
Late Breaking Presentation: Attention! Cytokinetics ($CYTK
https://doi.org/10.1056/NEJMoa2401424 10. Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A A key message from both ...
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. New England Journal of Medicine. DOI: 10.1056/NEJMoa2401424. APA workgroup update maintains ...
New England Journal of Medicine. DOI: 10.1056/NEJMoa2401424. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy – ...
... 10.1056/NEJMoa2401424. UCSF: University of California San Francisco. (n.d.) "Hypertrophic Cardiomyopathy." https://www.ucsfhealth.org ...
doi:10.1056/NEJMoa2401424. 7. Aficamten vs placebo in adults with symptomatic obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM) ...
Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424; Hartman JJ ...
doi:10.1056/NEJMoa2401424; Garcia-Pavia P, Maron MS, Masri A, et al. Aficamten or metoprolol monotherapy for obstructive hypertrophic ...
Maron, MS, et al. aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424; Hartman JJ ...
doi:10.1056/NEJMoa2401424. Hartman JJ, Hwee DT, Roebrt-Paganin J, et al. Aficamten is a small-molecule cardiac myosin inhibitor designed to ...
doi:10.1056/NEJMoa2401424; Hartman JJ, Hwee DT, Roebrt-Paganin J, et al. Aficamten is a small-molecule cardiac myosin inhibitor designed to ...
Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424; Chuang C ...
References. Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424 ...
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424; Chuang C, Collibee S, Ashcraft L ...
DOI: 10.1056/NEJMoa2401424. Chuang C, Collibee S, Ashcraft L, et al. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin ...
Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424; Chuang C ...
... 10.1056/NEJMoa2401424. UCSF: University of California San Francisco. (n.d.) "Hypertrophic Cardiomyopathy." https://www.ucsfhealth.org ...
doi:10.1056/nejmoa2401424. Maron MS, Masri A, Nassif ME, et al. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2401424?query=TOC&cid=DM2342985_Non_Subscriber&bid=-1972640637.
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424; CVrg: Heart Failure 2020-2029, p 44 ...
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424; CVrg: Heart Failure 2020-2029, p 44 ...
DOI: 10.1056/NEJMoa2401424. CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 ...
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424; CVrg: Heart Failure 2020-2029, p 44 ...
DOI: 10.1056/NEJMoa2401424. CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 ...
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424; CVrg: Heart Failure 2020-2029, p 44 ...
... 10.1056/NEJMoa2401424). In addition, cardiac structure and function measures improved significantly, as adjudicated by the Echocardiography ...
... 10.1056/NEJMoa2401424. Procedures for Hypertrophic Cardiomyopathy: Frontiers in Surgery. (2022.) “Endocardial Radiofrequency Ablation vs ...
Arquivos suplementares necessários. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2401424 DOI: 10.1056/NEJMoa2401424 PMID: 38739079.
Supplemental Files required. URL : https://www.nejm.org/doi/full/10.1056/NEJMoa2401424 DOI: 10.1056/NEJMoa2401424 PMID: 38739079.
追加ファイルが必要です。 URL : https://www.nejm.org/doi/full/10.1056/NEJMoa2401424 DOI: 10.1056/NEJMoa2401424 PMID: 38739079.
Ek Dosyalar gerekli. URL : https://www.nejm.org/doi/full/10.1056/NEJMoa2401424 DOI: 10.1056/NEJMoa2401424 PMID: 38739079.
Ergänzende Dateien erforderlich. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2401424 DOI: 10.1056/NEJMoa2401424 PMID: 38739079.
Se requieren archivos suplementarios. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2401424 DOI: 10.1056/NEJMoa2401424 PMID: 38739079.
DOI: 10.1056/NEJMoa2401424 PMID:38739079 URL: Aficamten para cardiomiopatia hipertrófica obstrutiva sintomática | New England Journal of ...
DOI: 10.1056/NEJMoa2401424 PMID:38739079 URL: Aficamten para la Cardiomiopatía Hipertrófica Obstructiva Sintomática | New England Journal of ...
DOI: 10.1056/NEJMoa2401424 PMID:38739079 URL: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of ...
DOI: 10.1056/NEJMoa2401424 PMID:38739079 URL: Aficamten para la cardiomiopatía hipertrófica obstructiva sintomática | New England Journal of ...
DOI: 10.1056/NEJMoa2401424 PMID:38739079 URL: Aficamten per Cardiomiopatia Ipertrofica Ostruttiva sintomatica | New England Journal of ...
DOI: 10.1056/NEJMoa2401424 PMID:38739079 URL: Aficamten para sa mga may Simtomatikong Obstructive Hypertrophic Cardiomyopathy | New England ...
DOI : 10.1056/NEJMoa2401424 PMID : 38739079 URL : Aficamten pour la cardiomyopathie hypertrophique obstructive symptomatique | Journal de ...
https://www.nejm.org/doi/10.1056/NEJMoa2401424?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Journal Club ...
आपकी सबमिशन के लिए धन्यवाद! कृपया निम्नलिखित को पढ़ें। जब आपका अनुरोध मिल जाए तो पूर्ति करने वाले को "धन्यवाद समाधान ...
DOI: 10.1056/NEJMoa2401424 Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2401424.
DOI: 10.1056/NEJMoa2401424 Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2401424.
... 10.1056/NEJMoa2401424 Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy · Pour en savoir plus et partager vos commentaires.
org/doi/full/10.1056/NEJMoa2401424. nejm.org. Aficamten for Symptomatic Obstructive Hypertrophic. 1 yr. Recent Posts. Cập nhật thông tin về y tế.
DOI: 10.1056/NEJMoa2401424. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy | New England Journal of Medicine (nejm.org).
... 10.1056/NEJMoa2401424. Secondary Source. New England Journal of Medicine. Source Reference: Ommen SR "Sixty years of hemodynamic pharmacology ...
doi.org/10.1056/NEJMoa2401424. Be the first to rate this article. Posted in: Drug Trial News | Medical Condition News. Comments (0). Download ...
People with HCM, chemists, scientists, medical doctors, academics, coordinators, operations professionals, investors, statisticians, and the ...
People with HCM, chemists, scientists, medical doctors, academics, coordinators, operations professionals, investors, statisticians, and the ...
(2024). “Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.” https://www.nejm.org/doi/full/10.1056/NEJMoa2401424. Procedures ...
DOI: 10.1056/NEJMoa2401424. CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 ...
doi:10.1056/NEJMoa2401424; European Society of Cardiology. Sequoia-HCM Trial Meets Primary endpoint in obstructive hypertrophic ...
... 10.1056/NEJMoa2401424, https://www.nejm.org/doi/full/10.1056/NEJMoa2401424. This research was supported by Cytokinetics. In the interest of ...
Treatment with aficamten increased peak oxygen uptake by 1.7 mL/kg/minute over 24 weeks compared with placebo.
... 10.1056/NEJMoa2401424, https://www.nejm.org/doi/full/10.1056/NEJMoa2401424. This research was supported by Cytokinetics. In the interest of ...
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424; CVrg: Heart Failure 2020-2029, p 44 ...
DOI: 10.1056/NEJMoa2401424. CVrg: Heart Failure 2020-2029, p 44 ... 10.1056/NEJMra1710575. Symphony Health 2016-2021 Patient Claims Data ...
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMoa2401424; CVrg: Heart Failure 2020-2029, p 44 ...
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2024; DOI: 10.1056/NEJMoa2401424. Cite This ...
2024;doi:10.1056/NEJMoa2401424. For more information: Martin S. Maron, MD, can be reached at martin.maron@lahey.org; X (Twitter): ...
Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. https://www.nejm.org/doi/full/10.1056/NEJMoa2401424; Mazzarotto F, et al ...
N
TH
DR
AM
SM
축
MA
AA
CC
ÁF
NS
SC
東循
CC
東公
NM
く
ME
EM
B
JF
JA
ME
JC
CS
JN
MM
GG
W
VJ
TM
TP
เพ
SA
FP
A
A
RB
AS
AM
AB
KD
AK
J
IO
EI
AM
AR
DH
FM
MS
JP
ZH
旅T
CM
M
D
BD
AM
MM
PT
WH
LC
NM
JG
ME
RV
UH
أا
MC
NL
NA
BL
AT
MM
A
RB
JS
MA
MC
CE
GF
P
CN
SS
SM
ML
JO
LL
IM
JM
CS
HH
YK
RT
MC
PK
XJ
BS
村元
SA
S
MP
AT
CC